Renal Effects of Sodium Phosphate Preparations
Sodium phosphate preparations cause acute phosphate nephropathy—a potentially irreversible form of kidney injury characterized by calcium phosphate crystal deposition in renal tubules—and should not be used as a first-line bowel preparation agent. 1
Mechanism of Kidney Injury
Sodium phosphate (NaP) solutions are hyperosmotic agents that induce phosphate-induced renal disease through calcium phosphate crystal precipitation in the distal tubules and collecting ducts. 2 The oral solution formulation (Fleet Phospho-Soda) was withdrawn from the U.S. over-the-counter market in December 2008 specifically due to concerns about phosphate-induced renal disease, though a prescription tablet formulation (OsmoPrep) remains available with a boxed warning about acute phosphate nephropathy risk. 1
Clinical Patterns of Renal Injury
Two distinct patterns of kidney damage occur with sodium phosphate preparations:
- Acute kidney injury (AKI): Presents with acute renal failure requiring potential hemodialysis, with some patients never recovering baseline function 3
- Chronic kidney disease: More common presentation (75% of cases in one series), characterized by insidious, progressive renal insufficiency without acute symptoms 3
The average irreversible loss of estimated glomerular filtration rate is 24 mL/min/1.73 m² in patients who develop phosphate nephropathy, even after a single dose. 3
Electrolyte Disturbances
Beyond structural kidney damage, sodium phosphate preparations cause severe electrolyte abnormalities:
- Hyperphosphatemia with compensatory severe hypocalcemia (potentially causing tetany) 4
- Hypokalemia 4
- Hypernatremia 2, 4
These disturbances can be life-threatening, particularly in at-risk populations. 4
High-Risk Populations (Absolute Contraindications)
The U.S. Multi-Society Task Force on Colorectal Cancer explicitly states that NaP is not recommended in the following populations: 1
- Renal insufficiency: Creatinine clearance <60 mL/min/1.73 m² 1
- Pre-existing electrolyte disturbances 1
- Congestive heart failure: NYHA class III or IV, or ejection fraction <50% 1
- Cirrhosis or ascites 1
- Children younger than 12 years of age 1, 5
Populations Requiring Extreme Caution
Use caution when prescribing NaP to patients who are: 1
- Elderly (particularly those >55 years) 2
- Hypertensive 1
- Taking angiotensin-converting enzyme inhibitors 1, 6
- Taking nonsteroidal anti-inflammatory drugs 1
- Taking diuretics 1
- Women with lower-than-average body weight (mean 68.57 kg vs. national average 74 kg) 7
Linear regression analysis demonstrates that ACE inhibitor/ARB use and diabetes are significant independent predictors of GFR decline after sodium phosphate exposure. 6
Long-Term Renal Effects in "Low-Risk" Patients
Even in patients with baseline normal creatinine levels undergoing routine colonoscopy, sodium phosphate causes measurable chronic kidney damage:
- Baseline GFR of 79 mL/min/1.73 m² declined to 73 mL/min/1.73 m² at 6 months post-exposure 6
- This decline was statistically significant compared to matched controls whose GFR remained stable 6
- Only 17% of patients (2 of 12) with documented phosphate nephropathy fully recovered their previous renal function 3
Clinical Recommendation
Although NaP is effective and well tolerated by most patients, the risk of adverse events makes it unsuitable as a first-line agent. 1 The U.S. Multi-Society Task Force recommends polyethylene glycol-electrolyte lavage solution (PEG-ELS) as the preferred regimen in patients less likely to tolerate fluid shifts, including those with renal insufficiency, congestive heart failure, and advanced liver disease, because PEG-ELS formulations are iso-osmotic. 1
Available data suggest that sodium phosphate purgatives are relatively safe only in adequately hydrated, otherwise healthy adults younger than 55 years with documented normal renal function—but even in this population, routine use for elective and screening procedures should be discouraged. 2, 6